Contradictory results with high-dosage rifamycin in mice and humans

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 1103-

  Coates, A R M ^a   Hu, YanMin ^a   Jindani, A ^a   Mitchison, D A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMYCIN; RIFAPENTINE;

AREA UNDER THE CURVE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPUTUM ANALYSIS; TREATMENT RESPONSE; TUBERCULOSIS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 84872871144     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01705-12     Document Type: Letter

References (8)

1. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset J, Nuermberger EL 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344. doi:10.1371/journal.pmed.0040344.
2. Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW, Tuberculosis Trials Consortium. 2012. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: Study 29 of the Tuberculosis Trials Consortium. J. Infect. Dis. 206:1030-1040.
3. Mitchison DA. 2012. Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins. Int. J. Tuberc. Lung Dis. 16:1186-1189.
4. Hu Y, Mangan JA, Dhillon J, Sole KM, Mitchison DA, Butcher PD, Coates AR. 2000. Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J. Bacteriol. 182:6358-6365.
5. Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR. 2010. Resuscitation promoting factors reveal an occult population of tubercle bacilli in sputum. Am. J. Respir. Crit. Care Med. 181:174-180.
6. Dhillon J, Lowrie DB, Mitchison DA. 2004. Mycobacterium tuberculosis from chronic murine infections that grows in liquid but not on solid medium. BMC Infect. Dis. 4:51. doi:10.1186/1471-2334-4-51.
7. Jayaram R, Gaonkat S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nundi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124.
8. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mudluli KE, Karakousis PC, Grosset J, Nuermberger EL. 2012. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob. Agents Chemother. 56:4331-4340.